Facts & Figures

Research focus

Bayer Schering Pharma is active in the clinical development for new products as well as product-accompanying development of already marketed products through all ist business areas and indication areas.

In its internal research for active substances, Bayer Schering Pharma concentrates on four core areas: Oncology, Cardiology, Women´s Healthcare, and Diagnostic Imaging. In addition, our clinical development drives the introduction of new products as well as the further development of marketed products across all business areas.

In the long term, Bayer Schering Pharma strives for innovation leadership in the areas of cardiology, gynecological therapy and molecular imaging and wants to play a significant role in oncology.

At a glance


Research expenses 2009	1,572 million EUR
In percent of division sales 2009	15%- 17%
Employees in Research & Development	approx. 5,900 (as of Dec 31, 2009)
Main research sites	Berlin und Wuppertal, Germany and Berkeley, USA
Research focus	Berlin: Diagnostic Imaging, Oncology, Women’s Healthcare Wuppertal: Cardiology, Oncology Berkeley: Applied research and life cycle management in hemophilia and Multiple Sclerosis

Research locations

Research programs and activities are consolidated in three major sites: Berlin and Wuppertal in Germany, and Berkeley in USA.

The Berlin research group focuses on Diagnostic Imaging, Oncology and Women’s Healthcare. Wuppertal focuses on the company’s Hematology and Oncology research. Both locations have the technologies for target discovery, lead generation and optimization, drug metabolism and pharmacokinetics, as well as toxicology and clinical pharmacology.

Berkeley is an important global research and development center for protein-based biologics drug discovery and is the home of the modern Kogenate biological manufacturing facility, an innovative medication for the treatment of hemophilia.